Alembic to drive US generics growth after API slump
This article was originally published in Scrip
Alembic Pharmaceuticals of India expects strong growth in its international generics business, backed, among others, by a string of potential new introductions in the US and supplies under the tender business in Europe. The company is also eyeing the inhalation space, top management said.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.